Application Observation of Different Doses of Rosuvastatin Combined with Ticagrelor in Acute ST-Segment Elevation Myocardial Infarction after PCI

Abstract

Objectives: To analyze the application of different doses of rosuvastatin combined with ticagrelor in acute ST-segment elevation myocardial infarction (STEMI) after percutaneous coronary intervention (PCI). Methods: The clinical data of 72 patients with acute STEMI treated with PCI at People’s Hospital in Yuncheng County (from July 2018 to July 2019) were retrospectively analyzed and 64 patients who met the research conditions were selected as the study subjects. Then, they were assigned to a low-dose group (LDG, n = 34, 10 mg of rosuvastatin + ticagrelor) and a high-dose group (HDG, n = 30, 20 mg of rosuvastatin + ticagrelor) according to different treatment methods. The indexes such as cardiac troponin I (cTnI) and renal function in the first examination and reexamination after surgery of both groups were detected to evaluate the clinical value of different medication schemes. Results: At 48 h after PCI (T2), the cTnI and creatine kinase isoenzyme (CK-MB) levels were notably lower in HDG than in LDG (p < 0.001). No obvious differences were found in the renal function indexes between HDG and LDG at different time points (p > 0.05). After treatment, the Myocardial Infarction Dimensional Assessment Scale (MIDAS) score in HDG was markedly lower than that in LDG (p < 0.001). Conclusions: Rosuvastatin can effectively improve the cTnI level and quality of life of patients with acute STEMI after PCI, and high-dose rosuvastatin has a better treatment effect. Further research is helping to provide an accurate solution for such patients.